Health Care • Biotechnology: Pharmaceutical Preparations
$73.16 ▲ +1.45
(+2.02%)
MKT CAP: $1.68B • VOL: 262.4K
52W L $70 52W H $96
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$61
MEDIAN
$82
MEAN
$83
HIGH
$100
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ANIP TAPE
ANIP // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $88.52 | $84.13 | 2025-02-14 | $66.58 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $92.18 | $86.33 | 2025-02-06 | $68.77 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $83.40 | $80.48 | 2025-01-29 | $70.23 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $74.62 | — | 2025-01-17 | $71.70 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $64.38 | $69.50 | 2025-01-09 | $65.11 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $87.06 | $76.09 | 2024-12-18 | $63.65 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $70.97 | $73.89 | 2024-12-04 | $68.04 | -4.3% | 48% | C |